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Abstract
Introduction: Bronchiectasis is a chronic disorder characterized by permanent dilation of the bronchi and 
bronchioles accompanied by inflammatory changes in the walls of these structures and adjacent lung paren-
chyma. Objective: The aim of the present study was to perform a clinical and functional characterization of 
adult patients with non-cystic fibrosis bronchiectasis. Methods: A clinical, descriptive, retrospective, case-
-series study was carried out involving 232 patients with non-cystic fibrosis bronchiectasis treated at a lung 
¹ Authors’ contributions: all the authors contributed to the conception and design the study. LVFO and NSFJ provided the idea for the 
study, established the hypothesis and wrote the original proposal. NSFJ conducted the data collection. AMB, SRS and FSSLF carried 
out pulmonary function tests. NSFJ, FSSLF and LVFO analyzed the data. This research paper was written by NSFJ, FSSLF and LVFO, 
with input from all co-authors. All authors significantly contributed to this study and read and approved the final manuscript
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ambulatory between 2004 and 2012. Results: The sample consisted of 232 patients (134 females; mean age: 
52.9 years ± 17.7; body mass index: 23.5 kg/m2 ± 4.4). The predominant symptoms were cough (91.4%), ex-
pectoration (85.8%) and dyspnea (76.3%). The majority of cases were of a non-tuberculosis etiology (64.7%). 
Regarding lung function, the obstructive breathing pattern was predominant (43.5%). The most common 
comorbidities were of a cardiovascular origin (51.0%). Conclusions: Adult patients with non-cystic fibrosis 
bronchiectasis (mainly post-infection or post-tuberculosis in origin) are characterized by a low educational 
level, excessive cough, sputum, dyspnea, muscle fatigue, an obstructive breathing pattern with frequent hypo-
xemia and multiple comorbidities, mainly of a cardiovascular origin. However, our patients have a low index of 
exacerbations and hospitalizations that can be assigned to a clinical protocol for monitoring. 
 [P]
Keywords: Bronchiectasis. Cough. Lung injury. Respiratory function test. Quality of life. 
[B]
Resumo
Introdução: Bronquiectasia é uma doença crônica caracterizada pela dilatação permanente dos brônquios e 
bronquíolos acompanhada por alterações inflamatórias nas paredes dessas estruturas e parênquima pulmo-
nar adjacente. Objetivo: O objetivo do presente estudo é realizar uma caracterização clínica e funcional de pa-
cientes adultos com bronquiectasias e fibrose não cística. Métodos: Um estudo clínico descritivo e retrospectivo 
foi realizado com pacientes com bronquiectasias e fibrose não cística atendidos em um ambulatório de pulmão 
entre 2004 e 2012. Resultados: A amostra foi composta por 232 pacientes (134 mulheres, idade média: 52,9 
anos ± 17,7, índice de massa corporal: 23,5 ± 4,4 kg/m2). Os sintomas predominantes foram tosse (91,4%), 
expectoração (85,8%) e dispneia (76,3%). A maioria dos casos foi de etiologia não tuberculosa (64,7%). Em 
relação à função pulmonar, o padrão de respiração obstrutiva foi predominante (43,5%). As comorbidades 
mais comuns foram de origem cardiovascular (51,0%). Conclusões: pacientes adultos com bronquiectasias 
de fibrose não cística (principalmente pós-infecção ou pós-tuberculose de origem) são caracterizados por um 
baixo nível de escolaridade, tosse excessiva, expectoração, dispneia, fadiga muscular, um padrão de respiração 
obstrutiva com hipoxemia frequente e múltiplas comorbidades, essencialmente de origem cardiovascular. No 
entanto, nossos pacientes têm um baixo índice de exacerbações e hospitalizações que podem ser atribuídos a 
um protocolo clínico para o acompanhamento.
 [K]
Palavras-chave: Bronquiectasia. Tosse. Lesão pulmonar. Teste de função respiratória. Qualidade de vida. 
Introduction2 
Bronchiectasis is a chronic disorder characterized 
by permanent dilation of the bronchi and bronchi-
oles accompanied by inflammatory changes in the 
walls of these structures and adjacent lung paren-
chyma due to repeated infection and inflammatory 
insults, leading to impaired mucociliary clearance 
and the excessive production of sputum (1-3). This 
condition is more frequent in females and gener-
ally occurs in the sixth decade of life (4). The most 
common clinical manifestations are chronic cough, 
fever, excessive purulent expectoration, sinusitis and 
muscle fatigue (4, 5).
The prevalence of bronchiectasis is not well de-
fined and likely varies significantly between popula-
tions (6). It is estimated that at least 110,000 adult 
patients in the United States of America (USA) are 
diagnosed with bronchiectasis, with prevalence rates 
of 4.2/100,000 individuals between 18 and 34 years 
of age and 272/100,000 individuals aged 75 years 
or older (7). Particular demographic groups are at 
greater risk for bronchiectasis, such as those with 
little access to health care and high rates of lung 
¹ Abbreviations: HRCT, high-resolution computed tomography; mmol/L, micromoles per liters; BMI, body mass index; IgE, imuno-
globulin; g/m2, grams per square meter; ml, milliliter; mm, millimeter; FVC, Forced vital capacity; FEV1, forced expiratory volume 
in the first second; SD, standard deviation; PaO2, parcial pressure of oxygen; SaO2, oxygen saturation; PaCO2, parcial pressure of 
carbon dioxide; SpO2, periferic saturation of oxygen. 
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infection in childhood (2). In a study carried out at a 
Brazilian hospital specialized in lung diseases, 0.4% 
(n = 170) of the total number of hospitalizations
(n = 42,500) between 1978 and 2001 were diagnosed 
as bronchiectasis (8).
High-resolution computed tomography (HRCT) of 
the thorax (9-11), which is currently the gold standard 
for the diagnosis of this condition, has demonstrated 
that bronchiectasis is a major respiratory disease (4, 6). 
Despite the increasingly frequent diagnosis of bronchi-
ectasis not associated with cystic fibrosis, especially in 
developing countries, the general and functional char-
acteristics of patients have been under-investigated. 
The aim of the present study was to describe the 
clinical and lung function profile of adult patients with 
non-cystic fibrosis bronchiectasis, offering a compari-
son of tuberculosis and non-tuberculosis etiologies.
Methods 
Subjects and study design
A clinical, descriptive, retrospective, case-series 
study was carried out. Medical files from 232 patients 
referred to a lung clinic in Brazil between 2004 and 2012 
were reviewed. The inclusion criteria were a clinical his-
tory compatible with bronchiectasis (dry or productive 
cough and/or report of recurring respiratory infection) 
and thorax HRCT compatible with bronchiectasis. The 
exclusion criteria were bronchiectasis stemming from 
cystic fibrosis (chloride level in sweat > 60 mmol/L). 
Ethical considerations
The study will be conducted based on the ethi-
cal standards established in the 1961 Declaration 
of Helsinki (as revised in Hong Kong in 1989 and 
Edimburgh, Scotland in 2000), and is in compli-
ance with the Regulatory Guidelines and Norms for 
Research Involving Human Subjects of the National 
Health Board of the Brazilian Health Ministry issued 
in October 1996, and was approved by the Human 
Research Ethics Committee of the Universidade Nove 
de Julho, Brazil (protocol n. 329759/2010). All par-
ticipants signed a statement of informed consent and 
will be allowed to abandon the study at any time with 
no negative consequences. All procedures of the study 
was confidential.
Clinical assessment
Patient histories with a suspicion of bronchiec-
tasis were collected by a pulmologist, who also per-
formed the physical exams. The following aspects 
were investigated: patient’s report of main respira-
tory complaints; the presence of cyanosis and comor-
bidities; pulmonary auscultation; weight, height and 
body mass index (BMI); current and/or past smoking 
habits (expressed in pack years); schooling; medica-
tions in use, lung function and blood gas analysis. 
For the investigation of the etiology of bronchi-
ectasis, the patients were routinely submitted to the 
following exams: microbiological exam of sputum 
(cultures for acid/alcohol-resistant bacilli), immuno-
globin levels (including IgE), chloride level in sweat 
and sperm analysis in cases of male patients with 
report or suspicion of associated infertility. 
The method used for determining chloride in the 
sweat was pilocarpine iontophoresis, which is con-
sidered the best method of sweat stimulation (12, 
13). Sweat was collected for 30 minutes onto pre-
weighed gauze or filter paper low in sodium chlo-
ride. A minimum sweat rate of 1 g/m2 body surface 
area/min was required. A volume of 50 to 100 ml was 
considered adequate. A sweat chloride level above 
60 mmol/l on two different tests was used to rule 
out cystic fibrosis (13).
HRCT of the thorax
All patients underwent HRCT of the chest 
(HiSpeed Advantage; General Electric Medical 
Systems, Milwaukee, WI, USA). High-resolution 
images were obtained in full inspiration for all pa-
tients, while expiratory images were acquired from 
patients suspected of having small airway disease. 
High-resolution images were obtained at 1-mm 
collimation at 1-mm intervals from the lung apices 
to the bases. Images were reconstructed with an 
algorithm using standard window setting (win-
dow level: 700 HU; window width: 1500 HU). The 
presence of bronchiectasis was based on 1) lack 
of tapering of the bronchi, 2) bronchial dilatation 
(when the internal diameter was at least 110% 
larger than the adjacent pulmonary artery) or
3) visualization of the peripheral bronchi with-
in 1 cm of the costal pleural surface or adjacent 
mediastinal pleural surface (14). Cylindrical 
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Results
Table 1 displays the demographic data on the en-
tire sample (n = 232). Mean age was 52.9 years ± 17.7. 
The female gender was predominant (57.8%). Mean 
BMI was 23.5 Kg/m2 ± 4.4; 22.9% of the patients had 
a BMI < 20.0 kg/m2, 40.9% had a BMI between 20.0 
and 25.0 kg/m2 and 36.2% had a BMI ≥ 25.0 kg/m2. 
Eighty-two patients (36.2%) were ex-smokers (vol-
ume ranging from 2.5 to 100 pack years). Only four 
patients were current smokers. A total of 64.6% of 
the sample had a low level of schooling (incomplete 
elementary education).
The majority of cases of non-cystic fibrosis bron-
chiectasis were of a non-tuberculosis etiology (64.7%), 
most often attributed to post-infection causes (39.6%) 
and idiopathic causes (18.5%) (Table 2). The predom-
inant symptoms were cough (91.4%), expectoration 
(85.8%) and dyspnea (76.3%). No significant differ-
ences were found between groups (tuberculosis versus 
non-tuberculosis etiology) regarding the distribution of 
symptoms (Table 3). The most frequent sign was crack-
ling sound (137 cases; 59%).
Regarding lung function, the obstructive breathing 
pattern was predominant (43.5%), followed by the re-
strictive (15.9%) and mixed (9.9%) patterns. Table 4
displays the distribution of the spirometric findings 
based on the guidelines of the American Thoracic 
Society/European Respiratory Society) (17) among 
patients with tuberculosis and non-tuberculosis eti-
ologies. No statistically significant differences were 
found between groups (p = 0.63). Moreover, thirty 
patients had normal spirometric readings. 
Table 5 displays the spirometric and blood gas 
analysis findings according to infectious and non-
infectious etiologies. Once again, no statistically 
significant differences were found between groups. 
The blood gas analysis revealed the presence of gas-
exchange abnormalities in some patients: 65 patients 
(32.8%) exhibited hypoxemia, among which 13 cas-
es (5.6%) had parcial pressure of oxygen (PaO
2
) ≤ 
55 mmHg, 10 cases (4.3%) had oxygen saturation 
(SaO
2
) ≤ 88% and 15 cases (6.5%) exhibited hyper-
capnia (parcial pressure of carbon dioxide - PaCO
2 
≥ 
45 mmHg). Fifteen patients (6.5%) were under pro-
longed home-based oxygen therapy (11 cases in the 
group with a non-tuberculosis etiology). 
The most common comorbidities were of a cardio-
vascular origin (51.0%), especially systemic arterial 
hypertension. One hundred seventy-five of the patients 
bronchiectasis was diagnosed based on dilatation 
and thickening of the bronchial wall (bronchial 
wall: arterial wall ratio > 1) (15) and cystic bron-
chiectasis was diagnosed by the presence of thin-
walled cystic spaces that may contain fluid seen in 
subsequent axial cuts either agglomerated or in a 
branching pattern (16). 
Pulmonary function testing and blood gas 
analysis 
All patients underwent forced spirometry follow-
ing the guidelines of the American Thoracic Society/
European Respiratory Society (17). Forced vital ca-
pacity (FVC), forced expiratory volume in the first 
second (FEV1) and FEV1/FVC ratio were measured 
prior to and 15-20 minutes after the use of a short-
acting bronchodilator (albuterol 400 mcg) (18).
All tests were performed during clinical stability (no 
occurrence of increased dyspnea, increased sputum 
and/or change in sputum purulence or change in 
medication use), with the discontinuation of short-
acting and long-acting β2-agonists six and 12 hours 
prior to the test, respectively. When a patient had 
more than one spirometric reading in the previous 
three months, the most recent was considered for 
analysis. 
The lung function tests were carried out using an 
Elite spirometer (Med Graphics Corporation; St Paul, 
MN, USA). Arterial blood samples were collected in 
heparinized blood-gas syringes and analyzed using a 
benchtop blood-gas analyzer (pHOx Stat Profile Plus L,
Nova Biomedical, Waltham MA, USA).
Statistical analysis
Descriptive and numerical data were reported 
as mean ± standard deviation (SD) or mean with 
± 95% confidence interval. Comparisons between 
groups (tuberculosis versus non-tuberculosis etiol-
ogy) were performed using the Student’s t-test or 
Mann-Whitney U test, depending on the type of data 
distribution. Pearson’s chi-squared test was used to 
compare proportions (categorical data) between the 
two groups. The level of statistical significance was 
set at 5% (p < 0.05) for all tests. The SPSS Version 16.0 
statistical software was used for the data analysis 
(IBM, Chicago, IL, USA).
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Table 1– Demographic and anthropometric characteristics of sample
Characteristics n = 232
Age (years) 52.9±17.7
Sex
          Male 98 (42.2%)
          Female 134 (57.8%)
Weight (Kg) 60.9±12.6
Body mass index (Kg/m2) 23.5±4.4
Smokers (current and ex-smokers) 82 (36.2%)
Pack years 21.7±15.3
Education
          - Low 64.6%
          - Medium 5.6%
          - High 29.8%
Characteristics n = 232
Age (years) 52.9±17.7
Sex
          Male 98 (42.2%)
          Female 134 (57.8%)
Weight (Kg)   60.9±12.6
Body mass index (Kg/m2) 23.5±4.4
Smokers (current and ex-smokers) 82 (36.2%)
Pack years   21.7±15.3
Education
          - Low 64.6%
          - Medium 5.6%
          - High 29.8%
Characteristics n = 232
Age (years)   52.9±17.7
Sex
          Male 98 (42.2%)
          Female 134 (57.8%)
Weight (Kg)   60.9±12.6
Body mass index (Kg/m2) 23.5±4.4
Smokers (current and ex-smokers) 82 (36.2%)
Pack years  21.7±15.3
Education
          - Low 64.6%
          - Medium 5.6%
          - High 29.8%
Characteristics n = 232
Age (years) 52.9±17.7
Sex
          Male 98 (42.2%)
          Female 134 (57.8%)
Weight (Kg) 60.9±12.6
continues
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Table 1– Demographic and anthropometric characteristics of sample
Characteristics n = 232
Body mass index (Kg/m2) 23.5±4.4
Smokers (current and ex-smokers) 82 (36.2%)
Pack years                                          21.7±15.3
Education
          - Low 64.6%
          - Medium 5.6%
          - High 29.8%
Legend: Kg = kilogram; m2 = square meters.
Source: Research data.
Note: Data expressed as mean ± SD for parametric data and as percentages for categorical data.
conclusion
Table 2 – Causes of non-cystic fibrosis bronchiectasis (n = 232)
Causes of non-cystic fibrosis bronchiectasis n = 232
Post-infection1




Kartagener’s syndrome3 6 (2.6%)
Rheumatoid arthritis 4 (1.8%)
Primary ciliary dyskinesia4 1 (0.4%)
Toxic inhalation 1 (0.4%)
Ulcerative colitis 1 (0.4%)
Immune deficiencies 1 (0.4%)
Mounier-Kühn syndrome5 1 (0.4%)
Causes of non-cystic fibrosis bronchiectasis n = 232
Post-infection1




Kartagener’s syndrome3 6 (2.6%)
Rheumatoid arthritis 4 (1.8%)
Primary ciliary dyskinesia4 1 (0.4%)
Toxic inhalation 1 (0.4%)
Ulcerative colitis 1 (0.4%)
Immune deficiencies 1 (0.4%)
Mounier-Kühn syndrome5 1 (0.4%)
Source: Research data.
Notes: 1Bronchiectasis with diagnosis established following episodes of pneumonia and after childhood diseases, such as measles, chicken 
pox, etc.
2When etiology could not be determined following extensive clinical investigation.
3Form of primary ciliary dyskinesia characterized by chronic pansinusitis, bronchiectasis and situs inversus with dextrocardia.
4Diagnosis performed on male patient with infertility and compatible alterations in semen analysis.
5Rare clinical condition characterized by abnormal dilation of trachea and main bronchi; diagnosis established through measure of tracheal 
diameter on thorax HRCT.
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Table 4 – Distribution of spirometric pattern in patients with non-cystic fibrosis bronchiectasis according to etiology (tuberculosis 
versus non-tuberculosis)
Etiology
Tuberculosis (n = 63) Non-tuberculosis (n = 128)
Result
Normal 7 (11.1%) 23 (17.9%)
Obstructive 34 (53.9%) 67 (52.3%)
Restrictive 14 (22.2%) 23 (17.9%)
Mixed 8 (12.7%) 15 (11.7%)
Legend: p = 0.63 (chi-squared test).
Source: Research data.
Note: Data expressed as absolute numbers and percentages.
Table 5 – Forced spirometry and blood gases analysis in patients with non-cystic fibrosis bronchiectasis according to etiology (tubercu-
losis versus non-tuberculosis)
Variables* Tuberculosis etiology (n = 82) Non-tuberculosis etiology (n = 150) p†
Forces spirometry**
FVC (L) 2.24 ± 0.90 2.41 ± 0.93 0.21
FVC (% pred.) 66.7 ± 23.7 68.6 ± 19.2 0.56
FEV1 (L) 1.45 ± 0.75 1.58 ± 0.82 0.26
FEV1 (% pred.) 53.0 ± 25.1 55.6 ± 23.1 0.47
FEV1/FVC (%) 62.4 ± 16.5 64.7 ± 14.6 0.31
Post-FVC (L) 2.37 ± 0.86 2.52 ± 0.97 0.35
Post-FVC (% pred.) 69.1 ± 22.6 71.2 ± 18.8 0.52
Post-FEV1 (L) 1.48 ± 0.75 1.70 ± 0.86 0.11
Post-FEV1 (% pred.) 55.5 ± 26.5 58.1 ± 22.5 0.49
Post - FEV1/FVC (%) 63.4 ± 15.9 65.5 ± 14.8 0.37
Arterial gas analysis
pH 7.41 ± 0.03 7.41 ± 0.03 0.96
PaO2 (mmHg) 72.2 ± 11.9 70.7 ± 13.7 0.56
Table 3 – Symptoms observed in patients with non-cystic fibrosis bronchiectasis according to etiology (tuberculosis versus non-tuberculosis)
Variable Tuberculosis etiology (n = 82) Non-tuberculosis etiology (n = 150) p*
Cough 72 (87.8%) 140 (93.3%) 0.22
Expectoration 67 (81.7%) 131 (87.3%) 0.25
Dyspnea 66 (80.5%) 111 (74.0%) 0.33
Wheezing 54 (65.9%) 106 (70.7%) 0.46
Hemoptoic/Hemoptysis 39 (47.6%) 61 (40.7%) 0.33
Legend: * chi-squared test.
Source: Research data.
Notes: Data expressed in absolute numbers and percentages. 
continues
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The main symptoms were cough and sputum, 
which is in agreement with findings described in the 
international scientific literature (4, 5, 26). Moreover, 
dyspnea (shortness of breath), fatigue and hemoptysis 
were found in a large portion of the patients (76.3%, 
69.4% and 43.1%, respectively) (21, 26, 27). However, 
no differences were found between the two groups 
(tuberculosis and non-tuberculosis etiology) regard-
ing symptoms. The most common noise encountered 
during pulmonary auscultation was crackling, which is 
also in agreement with findings described in the inter-
national scientific literature (2, 21). 
Although related to bronchial dilation, non-cystic 
fibrosis bronchiectasis more often results in air flow 
obstruction, which partially explains the findings of 
inflamed bronchioles and sputum in the airways, re-
gardless of the tuberculosis or non-tuberculosis etiol-
ogy (28). In the present study, airway obstruction was 
predominantly moderate (40% to 60% of predicted 
FEV
1
) (29), which confirms findings described by King 
et al. (4) Mean SpO
2
 was 94% ± 3.8, which is within 
the range of normality. However, 32.8% of subjects 
were hypoxemic (30) and 5.6% had severe hypoxemia. 
Fifteen patients required home oxygen supplementa-
tion, among whom only four had a tuberculosis etiology, 
which apparently had no influence on this dependence.
Long-acting β
2
-agonists with inhaled corticoste-
roids were the most employed respiratory medica-
tions. Although there is no clear evidence regarding 
this form of treatment (31), many patients reported 
an improvement in symptoms. Anti-hypertensive 
agents and diuretics were the most employed non-
respiratory medications, which indirectly confirms 
systemic arterial hypertension as the most common 
comorbidity in the present study. In agreement 
(75.4%) made regular use of respiratory medications; 
69 (29.7%) used long-lasting β
2 
agonists, 45 (19.4%) 
used short-lasting β
2 
agonists/ipratropium, 39 (16.8%) 
used inhaled corticosteroids and 22 (9.5%) used short-
lasting β
2 
agonists/inhaled corticoid steroids. One hun-
dred eight patients (46.5%) made use of non-respirato-
ry medications, among which anti-hypertension drugs 
and diuretics figured prominently. 
Discussion 
In the present study, non-cystic fibrosis bron-
chiectasis was found predominantly in the female 
gender (57.8%) and was more common among in-
dividuals with a low level of schooling, which is a 
characteristic of developing countries, as described 
by King et al. (4) and Nicotra et al. (19). The mean 
BMI (23.5 ± 4.4 kg/m2) demonstrates that the pa-
tients were within the ideal weight range (20). Most 
subjects had never smoked (63.8%), which is similar 
to the findings described in the study by King et al. 
(21) and indicates little likelihood of an association 
with tobacco-related diseases. 
The main cause of non-cystic fibrosis bronchi-
ectasis in our patients was infection, followed by 
sequelae from pulmonary tuberculosis, which are 
also characteristics of developing countries (22-24). 
Together, these conditions accounted for 74.9% of the 
causes. Pasteur et al. (25) found the main causes to be 
idiopathic in origin (53%) and post-infection (29%), 
whereas these figures were respectively 18.5% and 
39.6% in the present study. These differences may be 
explained by the fact that pulmonary tuberculosis is 
not common in developed countries. 
Table 5 – Forced spirometry and blood gases analysis in patients with non-cystic fibrosis bronchiectasis according to etiology (tubercu-
losis versus non-tuberculosis)
Variables* Tuberculosis etiology (n = 82) Non-tuberculosis etiology (n = 150) p†
PaCO2 (mmHg) 40.6 ± 5.26 39.9 ± 5.70 0.53
HCO3 (mEq/L) 25.4 ± 3.85 25.0 ± 3.85 0.57
SaO2 (%) 93.5 ± 3.7 93.5 ± 3.58 0.98
Legend: * = Values presented as means ± SD; ** = Data available for 191 patients; †= Student’s t-test for two independent samples 
(tuberculosis versus non-tuberculosis etiology); FVC = forced vital capacity; FEV1 = forced expiratory volume in one second; SaO2 = arterial 
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pens H, Dodge J, et al. Diagnostic Working Group. Cys-
tic fibrosis: terminology and diagnostic algorithms. 
Thorax. 2006 Jul;61(7):627-35. 
14. Smith IE, Jurriaans E, Diederich S, Ali N, Shneerson JM,
Flower CD. Chronic sputum production: correla-
tions between clinical features and findings on high 
resolution computed tomographic scanning of the 
chest. Thorax. 1996;51(9):914–8. 
15. Kim JS, Müller NL, Park CS, Grenier P, Herold CJ. Cy-
lindrical bronchiectasis: diagnostic findings on thin-
section CT. AJR Am J Roentgenol. 1997;168(3):751-4.
16. Marti-Bonmati L, Catala FJ, Ruiz Perales F. Computed 
tomography differentiation between cystic bronchi-
ectasis and bullae. J Thorac Imaging. 1991;7(1):83-5.
17. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R,
Coates A, et al. Standardisation of spirometry. Eur 
Respir J. 2005 Aug;26(2):319-38.
with previous studies (32), 10% of the subjects 
were regularly using macrolides due to their anti-
inflammatory properties. 
Limitations of the study
Although unlikely, there may be cases of cystic 
fibrosis with a normal chloride level in the sweat and 
associated with bronchiectasis. 
Conclusions 
Based on the results of the present study carried 
out at in a real practice with non-cystic fibrosis bron-
chiectasis, the clinical profile of patients with bron-
chiectasis (mainly post-infection or post-tuberculosis 
in origin) is characterized by a low educational level, 
excessive cough, sputum, dyspnea, muscle fatigue, 
an obstructive spirometric pattern with a frequent 
hypoxemia and multiple comorbidities, mainly of a 
cardiovascular origin. However, our patients have a 
low index of exacerbations and hospitalizations that 
can be assigned to a clinical protocol for monitoring. 
All patients in the present study made regular use
(3 times a week) of azithromycin (250 mg), according 
to the clinical protocol.
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